

F. 研究発表

1. 論文発表

平成22年度

- 1: Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. *J Virol.* 2010 84(22):12048-57.
- 2: von dem Bussche A, Machida R, Li K, Loevinsohn G, Khandar A, Wang J, Wakita T, Wands JR, Li J. Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. *J Hepatol.* 2010 53(5):797-804.
- 3: Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, Kakinuma S, Kiyohashi K, Kitazume A, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Wakita T, Watanabe M. Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants. *Virology.* 2010 405(2):361-9.
- 4: Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. *Gastroenterology.* 2010 139(4):1355-64.
- 5: Kushima Y, Wakita T, Hijikata M. A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production. *J Virol.* 2010 84(18):9118-27.
- 6: Banaudha K, Orenstein JM, Korolnek T, St Laurent GC 3rd, Wakita T, Kumar A. Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis. *Hepatology.* 2010 51(6):1922-32.
- 7: Shirasaki T, Honda M, Mizuno H, Shimakami T, Okada H, Sakai Y, Murakami S, Wakita T, Kaneko S. La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication. *J Infect Dis.* 2010 202(1):75-85.
- 8: Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF. Hepatitis C virus controls interferon production through PKR activation. *PLoS One.* 2010 5(5):e10575.
- 9: Murayama A, Weng L, Date T, Akazawa D, Tian X, Suzuki T, Kato T, Tanaka Y, Mizokami M, Wakita T, Toyoda T. RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells. *PLoS Pathog.* 2010 6(4):e1000885.
- 10: Takahashi H, Akazawa D, Kato T, Date T, Shirakura M, Nakamura N, Mochizuki H, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Suzuki T, Wakita T. Biological properties of purified recombinant HCV particles with an epitope-tagged envelope. *Biochem Biophys Res Commun.* 2010 395(4):565-71.
- 11: Masaki T, Suzuki R, Saeed M, Mori K, Matsuda M, Aizaki H, Ishii K, Maki N, Miyamura T, Matsuura Y, Wakita T, Suzuki T. Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription. *J Virol.* 2010 84(11):5824-35.
- 12: Wu S, Imazeki F, Kurbanov F, Fukai K, Arai M, Kanda T, Yonemitsu Y, Tanaka Y, Mizokami M, Yokosuka O. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. *J Hepatol.* 54(1):19-25, 2011
- 13: Tanaka Y, Sugiyama M, Mizokami M. Direct cytopathic effects of particular hepatitis B virus genotypes in immunosuppressive condition. *Uirusu.* 60(1):79-86, 2010.
- 14: Kondo Y, Ueno Y, Kobayashi K, Kakazu E, Shiina M, Inoue J, Tamai K, Wakui Y, Tanaka Y, Ninomiya M, Obara N, Fukushima K, Ishii M, Kobayashi T, Niitsuma H, Kon S, Shimosegawa T. Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes. *J Infect Dis.* 202(2):202-13, 2010.

15. Tripathi, L. P., C. Kataoka, S. Taguwa, K. Moriishi, Y. Mori, Y. Matsuura, and K. Mizuguchi. 2010. Network based analysis of hepatitis C virus Core and NS4B protein interactions. *Mol. Biosyst.* 6:2539-2553.
16. Tanaka, Y., Y. Mori, H. Tani, T. Abe, K. Moriishi, H. Kojima, T. Nagano, T. Okabe, T. Suzuki, M. Tatsumi, and Y. Matsuura. 2010. Establishment of an indicator cell system for hepatitis C virus. *Microbiol. Immunol.* 54:206-220.
17. Moriishi, K., I. Shoji, Y. Mori, R. Suzuki, T. Suzuki, C. Kataoka, and Y. Matsuura. 2010. Involvement of PA28gamma in the propagation of hepatitis C virus. *Hepatology* 52:411-420.
18. Ariumi Y, Kuroki M, Maki M, Ikeda M, Dansako H, Wakita T, Kato N. The ESCRT System Is Required for Hepatitis C Virus Production. *PLoS ONE*, 6(1): e14517, 2011
19. Oshiumi H, Ikeda M, Matsumoto M, Watanabe A, Takeuchi O, Akira S, Kato N, Shimotohno K, Seya T. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN- β induction. *PLoS ONE*, 5(12): e14528, 2010.
20. Mori K, Ikeda M, Ariumi Y, Kato N. Gene expression profile of Li23, a new human hepatoma cell line enables robust hepatitis C virus replication: Comparison with HuH-7 and other hepatic cell lines. *Hepatology Res.*, 40:1248-1253, 2010.
20. Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouse K, Iwasaki Y, Ikeda M, Kato N, Yamamoto K. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon- α in vitro. *Liver Int.* 9: 1324-1331, 2010.
21. Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. *Arch Virol.*, 155:601-605, 2010.
22. Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, Miura S. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. *World J. Gastroenterol.*, 16:184-192, 2010.
23. N Sakamoto, M Nakagawa, Y Tanaka, Y Sekine-Osajima, M Ueyama, M Kurosaki, N Nishida, A Tamori, Y Nishimura- Sakurai, Y Itsui, S Azuma, S Kakinuma, S Hige, Y Ito, E Tanaka, Y Hiasa, N Izumi, K Tokunaga, M Mizokami, M Watanabe: Association of IL28B polymorphism with response to pegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C. *J Medical Virol* 2010; *in press*.
24. M Yamamoto, N Sakamoto, T Nakamura, Y Itsui, M Nakagawa, Y Nishimura- Sakurai, S Kakinuma, S Azuma, K Tsuchiya, T Kato, T Wakita, M Watanabe: Studies on virus kinetics using infectious fluorescence- tagged hepatitis C virus cell culture. *Hepatology Research* 2011; *in press*.
25. M Kurosaki, N Sakamoto, M Iwasaki, M Sakamoto, Y Suzuki, N Hiramatsu, F Sugauchi, A Tamori, M Nakagawa, N Izumi: Sequences in the Interferon Sensitivity Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to Peg-interferon Plus Ribavirin: Data Mining Analysis. *J Medical Virol* 2011; *in press*.
26. M Kurosaki, N Sakamoto, M Iwasaki, M Sakamoto, Y Suzuki, N Hiramatsu, F Sugauchi, H Yatsushashi, N Izumi: Pretreatment Prediction of response to peginterferon plus ribavirin in chronic hepatitis C using data mining analysis. *J Gastroenterol* 2010; *EPub*.
27. N Sakamoto, Y Tanaka, Mina N, H Yatsushashi, S Nishiguchi, N Enomoto, S Azuma, Y Nishimura-Sakurai, S Kakinuma, N Nishida, K Tokunaga, M Honda, K Ito, M Mizokami, M Watanabe: ITPA gene variant protects against anemia induced by pegylated interferon- α and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatology Research* 2010; 40(11):1063-1071.
28. G Suda, N Sakamoto, Y Itsui, M Nakagawa, K Mishima, Y Onuki-Karakama, M Yamamoto, Y Funaoka, T Watanabe, K Kiyohashi, S Nitta, S Azuma, S

- Kakinuma, K Tsuchiya, M Imamura, N Hiraga, K Chayama, M Watanabe: IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. *Virology* 2010; 407:80-90.
29. Y Karakama, N Sakamoto, Y Itsui, M Nakagawa, M Tasaka-Fujita, Y Nishimura-Sakurai, S Kakinuma, S Oooka, S Azuma, K Tsuchiya, H Onogi, M Hagiwara, M Watanabe: Inhibition of HCV replication by a specific inhibitor of serin-arginine-rich protein kinase. *Antimicrob Agent Chemother* 2010; 54 (8):3179-3186.
30. Tashiro K, Kawabata K, Inamura M, Takayama K, Furukawa N, Sakurai F, Katayama K, Hayakawa H, Furue-Kusuda M, Mizuguchi H. Adenovirus vector-mediated efficient transduction into human embryonic and induced pluripotent stem cells. *Cell Reprogram.*, 12, 501-507 (2010)
- 平成 23 年度
1. Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, Suzuki T, Wakita T. Production and characterization of HCV particles from serum-free culture. *Vaccine*. 2011 29(29-30):4821-8.
2. Aly HH, Oshiumi H, Shime H, Matsumoto M, Wakita T, Shimotohno K, Seya T. Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). *PLoS One*. 2011;6(6):e21284.
3. Amin EM, Hua J, Cheung MK, Ni L, Kase S, Ren-nel ES, Gammons M, Nowak DG, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton D, Bates DO, Ladomery MR. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. *Cancer Cell* 20(6):768-780.(2011)
4. Anwar A, Hosoya T, Leong KM, Onogi H, Okuno Y, Hiramatsu T, Koyama H, Suzuki M, Hagiwara M, Garcia-Blanco MA. The Kinase Inhibitor SFV785 Dislocates Dengue Virus Envelope Protein from the Replication Complex and Blocks Virus Assembly. *PLoS One*. 6(8):e23246.(2011)
5. Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M, Maki M, Ikeda M, Kato N. Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. *J. Virol.*, 85:6882-6892, 2011
6. Ariumi Y, Kuroki M, Maki M, Ikeda M, Dansako H, Wakita T, Kato N. The ESCRT System Is Required for Hepatitis C Virus Production. *PLoS ONE*, 6:e14517, 2011
7. Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, Wakita T, Meurs EF. Hepatitis C virus reveals a novel early control in acute immune response. *PLoS Pathog*. 2011 7(10):e1002289.
8. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response. *Hepatology*, 55(1):20-29, 2011
9. Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, Wakita T. Replication and Infectivity of a Novel Genotype 1b Hepatitis C Virus Clone. *Microbiol Immunol*. 2012 in press
10. Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. *J Med Chem*. 54(12):4172-4186.(2011)
11. Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, Watanabe T, Mishima K, Ueyama M, Onozuka I, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Watanabe M. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. *J Virol*, 85(12):5986-5994, 2011
12. Hikosaka K, Noritake H, Kimura W, Sultana N, Skarkar MTK, Tagawa Y, Uezato T, Kobayashi Y, Wakita

- T, Miura N. Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry. *Biomed Res*, 32: 143-150, 2011
13. Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, and Izumi N. Pretreatment Prediction of Anemia Progression by Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C: Decision-Tree Analysis. *J Gastroenterol* ,46 (9): 1111-1119, 2011
14. Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. *Gastroenterology*. 2011 141(1):128-40,140.e1-2.
15. Iikura M, Furihata T, Mizuguchi M, Nagai M, Ikeda M, Kato N, Tsubota A, Chiba K. ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. *Antimicrob. Agents Chemother.*, in press, 2012
16. Ikeda M, Kawai Y, Mori K, Yano M, Abe K, Nishimura G, Dansako H, Ariumi Y, Wakita T, Yamamoto K, Kato N. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C. *Liver Int*, 31:871-880, 2011
17. Inamura M., Kawabata K., Takayama K., Tashiro K., Sakurai F., Katayama K., Toyoda M., Akutsu H., Miyagawa Y., Okita H., Kiyokawa N., Umezawa A., Hayakawa T., Furue M.K., Mizuguchi H. Efficient generation of hepatoblasts from human ES cells and iPS cells by transient overexpression of homeobox gene HEX. *Mol. Ther.*, 19, 400-407 (2011)
18. Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N. Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. *Hepato Int* ,5(3):789-799, 2011
19. Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. *PLoS One* ,6 (9):e24514, 2011
20. Kakutani H, Takahashi A, Kondoh M, Sakihama T, Hamakubo T, Yagi K. A novel screening system for claudin binder using baculoviral display. *PLoS ONE*, 2011 Feb 14;6(2):e16611
21. Kambara, H., Tani, H., Mori, Y., Abe, T., Katoh, H., Fukuhara, T., Taguwa, S., Moriishi, K., and Matsuura, Y. (2011). Involvement of cyclophilin B in the replication of Japanese encephalitis virus. *Virology* 412, 211-219
22. Kataoka N, Diem MD, Yoshida M, 4, Hatai C, Dobashi I, Dreyfuss G, Hagiwara M, and Ohno M. Specific Y14 domains mediate its nucleo-cytoplasmic shuttling and association with spliced mRNA. *Scientific Reports* 1, doi:10.1038/srep00092. (2011)
23. Kaushik-Basu N, Sakamoto N. Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives. *Eur J Med Chem* , in press, 2012
24. Kawabata K., Inamura M., Mizuguchi H. Efficient hepatic differentiation from human iPS cells by gene transfer. *Methods Mol. Biol.*, 826, 115-124 (2012)
25. Kawabata K., Takayama K., Nagamoto Y., Saldon M.S., Higuchi M., Mizuguchi H. Endodermal and hepatic differentiation from human embryonic stem cells and human induced pluripotent stem cells. *J. Stem Cell Res. Ther.*, in press
26. Kimura W, Machii M, Xue X-D, Sultana N, Hikosaka K, Sharkar MTK, Uezato T, Matsuda M, Koseki H, Miura, N. Irx11 mutant mice show reduced tendon differentiation and no patterning defects in musculoskeletal system development. *Genesis* 49: 2-9, 2011.
27. Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y,

- Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Yatsushashi H, Izumi N. Age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy in chronic hepatitis C revealed by data mining analysis. *Antivir Ther*, in press, 2011
28. Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N. Data Mining Analysis of Hepatocellular Carcinoma Risk Predictors in Chronic Hepatitis C. *J Hepatol*, Epub ahead of Print, 2011
29. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsushashi H, Izumi N. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. *J Gastroenterol*, 46(3):401-409, 2011
30. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. *J Med Virol*, 83:445-452, 2011
31. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. *J Hepatol*, 54:439-448, 2011
32. Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyonashi K, Nitta S, Murakawa M, Azuma S, Nishimura-Sakurai Y, Hagiwara M, Watanabe M. Identification of novel N-(morpholine-4-carboxyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. *Antimicrob Agent Chemother*; Epub ahead of Print, 2011
33. Li, Y., Takebe, Y., Yang, J., Wei Zhang, W., Yang, R. (2011). High prevalence of HIV-1 subtype B' among heterosexuals in western Hubei, Central China: Bridging the epidemic into general population, *AIDS Res. Hum. Retrovirus*. 2011 Jan 27. [Epub ahead of print]
34. Li, Z., He, X., Li, F., Yang, Y., Wang, Q., Xing, H., Takebe, Y., Shao, Y. Tracing the origin and history of HIV-1 subtype B' epidemic in China by near full-length genome analyses. *AIDS*. 2012 Jan 20. [Epub ahead of print]
35. Mori K, Ueda Y, Ariumi Y, Dansako H, Ikeda M, Kato N. Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C. *Virus Genes*, in press, 2012
36. Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. *Virus Res*, 157: 61-70, 2011
37. Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T, Nakamoto S, Tanaka Y, Mizokami M, Yokosuka O, Nomoto A, Wakita T. Production of Infectious Chimeric Hepatitis C Virus Genotype 2b Harboring Minimal Regions of JFH-1. *J Virol*. 2012 86(4):2143-52.
38. Nakamura Y, Arai A, Takebe Y, Masuda M. A chemical compound for controlled expression of nmt1-driven gene in the fission yeast *Schizosaccharomyces pombe*. *Anal Biochem*. 2011 May 15;412(2):159-64
39. Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses. *Hepatol Res*. 2011;41(9):838-845
40. Nakano, K., Katano, H., Tadagaki, K., Sato, Y., Ohsaki, E., Mori, Y., Yamanishi, K., and Ueda, K. "Novel Monoclonal Antibodies for Identification of Multicentric Castleman's Disease; Kaposi's Sarcoma-Associated Herpesvirus-Encoded vMIP-I and

vMIP-II.” *Virology* in press

41. Ninomiya K, Kataoka N, and Hagiwara M. Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor. *J Cell Biol*. 195(1):27-40.(2011)
42. Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano, H, Ota, M, Itoh K, Hagiwara M, and Matsuo M. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. *Nature Commun* 2, 308.(2011)
43. Okamoto Y, Masaki T, Murayama A, Munakata T, Nomoto A, Nakamoto S, Yokosuka O, Watanabe H, Wakita T, Kato T. Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2. *Biochem Biophys Res Commun*. 2011 410(3):404-9.
44. Onozuka I, Kakinuma S, Kamiya A, Miyoshi M, Sakamoto N, Kiyohashi K, Watanabe T, Funaoka Y, Ueyama M, Nakagawa M, Koshikawa N, Seiki M, Nakauchi H, Watanabe M. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. *Biochem Biophys Res Commun* ,406:134-140, 2011
45. Raghwani, J., Thomas, X. V., Koekkoek, S. M., Schinkel, J., Molenkamp, R., van de Laar, T., Takebe, Y., Tanaka, Y., Mizokami, M., Rambaut, A. and Pybus, O. G. (2011). The origin and evolution of the unique HCV circulating recombinant form 2k/1b. *J Virol*. 2012 Feb;86(4):2212-20.
46. Sabine A, Agalarov Y, Hajjami NME, Jaquet M, Hagerling R, Pollmann C, Bebbler D, Pfenniger A, Miura N, Dormond O, Calmes JM, Adams R, Makinen T, Kiefer F, Kwak BR, Petrova TV: PROX1, FOXC2 and mechanotransduction cooperate to control connexin 37 and calcineurin during lymphatic valve formation. *Dev Cell*, in press
47. Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K, Liang TJ, Wakita T, Kato T. In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. *Hepatology*. 2011 54(2):425-33.
48. Saeed M, Suzuki R, Watanabe N, Masaki T, Tomonaga M, Muhammad A, Kato T, Matsuura Y, Watanabe H, Wakita T, Suzuki T. Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles. *J Biol Chem*. 2011 286(43):37264-73.
49. Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M, Ochanomizu-Liver Conference Study Group. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. *J Med Virol*,83:871-878, 2011
50. Salim MT, Aoyama H, Sugita K, Watashi K, Wakita T, Hamasaki T, Okamoto M, Urata Y, Hashimoto Y, Baba M. Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives. *Biochem Biophys Res Commun*. 2011 415(4):714-9.
51. Sa-Nguanmoo P, Tanaka Y, Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, Mizokami M, Poovorawan Y. Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes. *Virus Res*. 2011;158(1-2):209-215
52. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic Variation of the IL-28B Promoter Affecting Gene Expression. *PLoS One*. 2011;6(10):e26620.
53. Taguwa, S., Kambara, H., Fujita, N., Noda, T., Yoshimori, T., Koike, K., Moriishi, K., and Matsuura, Y. (2011). Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus. *J. Virol*. 85, 13185-13194
54. Takaya D, Yamashita A, Kamiyo K, Gomi J, Ito M, Maekawa S, Enomoto N, Sakamoto N, Watanabe Y, Arai R, Umeyama H, Honma T, Matsumoto T, Yokoyama S. A new method for induced fit docking (GENIUS) and its

- application to virtual screening of novel HCV NS3-4A protease inhibitors. *Bioorganic & Medicinal Chemistry*, 19(22):6892-6905, 2011
55. Takayama K., Inamura M., Kawabata K., Katayama K., Higuchi M., Tashiro K., Nonaka A., Sakurai F., Hayakawa T., Furue M.K., Mizuguchi H. Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4 α transduction. *Mol. Ther.*, 20, 127-137 (2012)
56. Takayama K., Inamura M., Kawabata K., Tashiro K., Katayama K., Hayakawa T., Furue M.K., Mizuguchi H. Efficient and selective generation of two distinct endoderm lineages from human ES and iPS cells by differentiation stage-specific SOX17 transduction. *PLoS One*, 6, e21780 (2011)
57. Tammela T, Zarkada G, NUrmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco C, Murtomaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard J, Gerhardt H, Alitaro K: VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signaling. *Nature Cell Biol* 13: 1202-1213, 2011
58. Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. *Human Molecular Genetics*, 20 (17):3507-3516, 2011
59. Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, Ikeda M, Kato N, Isomoto H, Tkashima F, Nakao K. Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells. *J Gastroenterol*, in press, 2011
60. Tee, K.K. Kamarulzaman, A., Matano, T., and Takebe Y. Phylogenetic inference of infectious diseases caused by the human immunodeficiency virus, enterovirus 71 and 2009 Swine-origin human influenza virus. *Future Virol.* 2011. In press
61. Toyoda M, Kitaoka A, Machida K, Nishinakagawa T, Yada R, Kohjima M, Kato M, Kotoh K, Sakamoto N, Shiota G, Nakamuta M, Nakashima M, Enjoji M. Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. *Int J Mol Med*, 27:619-624, 2011
62. Ueda Y, Mori K, Ariumi Y, Ikeda M, Kato N. Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents. *Biochem. Biophys. Res. Commun.*, 409:663-668, 2011
63. Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M, Ochanomizu-Liver Conference Study Group. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin. *Antivir Ther*, 16(7):1081-1091, 2011
64. Uezato T, Sato E, Miura N: Screening of natural medicines that efficiently activate neurite outgrowth in PC12 cells in C2C12-cultured medium. *Biomed Res*, in press
65. Urano E, Kuramochi N, Ichikawa R, Murayama SY, Miyauchi K, Tomoda H, Takebe Y, Nermut M, Komano J, Morikawa Y. Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system. *Antimicrob Agents Chemother.* 2011 Sep;55(9):4251-60.
66. Wang J, Singh US, Rawal RK, Sugiyama M, Yoo J, Jha AK, Scroggin M, Huang Z, Murray MG, Govindarajan R, Tanaka Y, Korba B, Chu CK. Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. *Bioorg Med Chem Lett.* 2011;21(21):6328-31

67. Wang B, Hikosaka K, Sultana N, Sharkar MTK, Noritake H, Kimura W, Wu Y-X, Kobayashi Y, Uezato T, Miura N: Liver tumor formation by a mutant retinoblastoma protein in the transgenic mice is caused by an up-regulation of c-Myc target genes. *Biochem Biophys Res Commun*, 417: 601-608, 2012
68. Watanabe T, Sakamoto N, Nakagawa M, Kakinuma S, Itsui Y, Nishimura-Sakurai Y, Ueyama M, Funaoka Y, Kitazume A, Nitta S, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Oooka S, Watanabe M. Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection. *Antimicrob Agents Chemother* , 55(6):2537-2545, 2011
69. Wen, X., Abe, T., Kukihara, H., Taguwa, S., Mori, Y., Tani, H., Kato, N., Suzuki, T., Tatsumi, M., Moriishi, K., and Matsuura, Y. (2011). Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules. *PLoS One* 6, e15967.
70. Weng L, Kohara M, Wakita T, Shimotohno K, Toyoda T. Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase. *Gene*. 2012 496(2):79-87.
71. Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, Wakita T, Suzuki T. Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus. *J Gen Virol*. 2011 92(Pt 9):2082-7.
72. Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-Sakurai Y, Kakinuma S, Azuma S, Tsuchiya K, Kato T, Wakita T, Watanabe M. Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture. *Hepatol Res* ,41:258-269, 2011
73. Yoshida T, Takayama K, Kondoh M, Sakurai F, Tani H, Sakamoto N, Matsuura Y, Mizuguchi H, Yagi K. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. *Biochem Biophys Res Commun* ,416(1-2):119-124, 2011
74. Yoshida T, Kondoh M, Ojima M, Mizuguchi H, Yamagishi Y, Sakamoto N, Yagi K. Adenovirus vector-mediated assay system for hepatitis C virus replication. *Nucleic Acids Res* ,39(10):e64, 2011
75. Yoshida T., Takayama K., Kondoh M., Sakurai F., Tani H., Sakamoto N., Matsuura Y., Mizuguchi H., Yagi K. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. *Biochem. Biophys. Res. Commun.*, 416, 119-124 (2011)
- 平成 24 年度
- 1) HH. Aly, K Shimotohno, M Hijikata, T Seya: In vitro models for the analysis of HCV life cycle, *Microbiol. and Immunol.*, 2012, 56, 1, 1-9.
 - 2) Ando T, Imamura H, Suzuki R, Aizaki H, Watanabe T, Wakita T, Suzuki T. Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA. *PLoS Pathog*. 2012;8(3):e1002561.
 - 3) Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N: Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response. *Hepatology* 2012; 55(1):20-29.
 - 4) Cheng J-C, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD: Let-7b is a novel regulator of hepatitis C virus replication. *Cell Mol Life Sci* 2012; 69(15):2621-2633.
 - 5) Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T. Novel Cell Culture-Adapted Genotype 2a Hepatitis C Virus Infectious Clone. *J Virol*. 2012 86(19):10805-20.
 - 6) Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, Wakita T. Replication and infectivity of a novel genotype 1b hepatitis C virus clone. *Microbiol Immunol*. 2012 56(5):308-17.
 - 7) Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, Maekawa S,

- Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, Moriishi K: Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp. *PLoS One*, 7: e48635, 2012
- 8) Iikura M, Furihata T, Mizuguchi M, Nagai M, Ikeda M, Kato N, Tsubota A, Chiba K. ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. *Antimicrob. Agents Chemother.*, 56(3):1407-13, 2012.
- 9) Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M: Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. *J Gastroenterol* 2012; 47(11):1228-1237.
- 10) Kondo M, Moriishi K, Wada H, Noda T, Marubashi S, Wakasa K, Matsuura Y, Doki Y, Mori M, Nagano H: Upregulation of nuclear PA28gamma expression in cirrhosis and hepatocellular carcinoma. *Exp. Ther. Med.*, 3: 379-385, 2012
- 11) Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N: Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. *J Hepatol* 2012;56(3):602-608.
- 12) Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Yatsuhashi H, Izumi N: Age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy in chronic hepatitis C revealed by data mining analysis. *Antivir Ther* 2012; 17:35-43.
- 13) Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyonashi K, Nitta S, Murakawa M, Azuma S, Nishimura-Sakurai Y, Hagiwara M, Watanabe M: Identification of novel N-(morpholine-4-carboxyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. *Antimicrob Agent Chemother* 2012; 56(3):1315-1323.
- 14) Mori K, Ueda Y, Ariumi Y, Dansako H, Ikeda M, Kato N. Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C. *Virus Genes*, 44(3):374-81, 2012.
- 15) Moriishi K, Matsuura Y: Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. *Front. Microbiol.*, 3: 54, 2012
- 16) Nichols DB, Fournet G, Gurukumar KR, Basu A, Lee JC, Sakamoto N, Kozielski F, Musmuca I, Joseph B, Ragno R, Kaushik-Basu N: Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives. *Eur J Med Chem* 2012; 49:191-199.
- 17) Murayama A, Sugiyama N, Yoshimura S, Ishihara-Sugano M, Masaki,T., Kim,S., Wakita,T., Mishiro,S., and Kato,T. A Subclone of HuH-7 with Enhanced Intracellular Hepatitis C Virus Production and Evasion of Virus Related-Cell Cycle Arrest. *PLoS One* 7 (12), e52697, 2012.
- 18) Murayama,A., Sugiyama,N., Watashi,K., Masaki,T., Suzuki,R., Aizaki,H., Mizuochi,T., Wakita,T., and Kato,T. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. *J Clin Microbiol* 50 (6), 1943-1949, 2012.
- 19) Murayama,A., Kato,T., Akazawa,D., Sugiyama,N., Date,T., Masaki,T., Nakamoto,S., Tanaka,Y., Mizokami,M., Yokosuka,O., Nomoto,A., and Wakita,T. Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. *J Virol* 86 (4), 2143-2152, 2012.
- Nagamoto Y., Tashiro K., Takayama K., Ohashi K., Kawabata K., Sakurai F., Tachibana M., Hayakawa T., Furue MK., Mizuguchi H. Promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets. *Biomaterials*, 33, 4526-4534 (2012)
- 20) Nitta S, Sakamoto N, Nakagawa M, Kakinuma S,

- Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M: Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity. *Hepatology* 2013; 57(1):46-58.
- 21) Raghwani, J., Thomas, X. V., Koekkoek, S. M., Schinkel, J., Molenkamp, R., van de Laar, T., Takebe, Y., Tanaka, Y., Mizokami, M., Rambaut, A. and Pybus, O. G. (2012). The origin and evolution of the unique HCV circulating recombinant form 2k/1b. *J Virol.* 2012 Feb;86(4):2212-20.
- 22) Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, Tanaka Y, Chu CK. 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: In vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. *Bioorg Med Chem Lett.* 2013; 23(2): 503-6.
- 23) Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. Replication of Hepatitis C Virus Genotype 3a in Cultured Cells. *Gastroenterology.* 2013 144(1):56-58.
- 24) Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S: Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. *Hepatol Res* 2012;42(10):958-965.
- 25) Sakamoto T, Tanaka Y, Kani S, Sugiyama M, Watanabe T, Iijima S, Murakami S, Matsuura K, Kusakabe A, Shinkai N, Sugauchi F, Mizokami M. Mechanism of the Dependence of Hepatitis B Virus Genotype G on Co-infection with Other Genotypes for Viral Replication. *J Viral. Hepat.*, 2012 in press.
- Sakurai F, Furukawa N, Higuchi M, Okamoto S, Ono K, Yoshida T, Kondoh M, Yagi K, Sakamoto N, Katayama K, Mizuguchi H: Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a. *Virus Research* 2012; 165(2):214-218.
- 26) Sejima H, Mori K, Ariumi Y, Ikeda M, Kato N. Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA. *Virus Res.*, 167(1):74-85,2012.
- 27) Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, Tanaka Y, Mizokami M. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. *Microbiol Immunol.* 2012 in press.
- 28) Suzuki R, Saito K, Kato T, Shirakura M, Akazawa D, Ishii K, Aizaki H, Kanegae Y, Matsuura Y, Saito I, Wakita T, Suzuki T. Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection. *Virology.* 2012 432(1):29-38.
- 29) Takayama K., Inamura M., Kawabata K., Sugawara M., Kikuchi K., Higuchi M., Nagamoto Y., Watanabe H., Tashiro K., Sakurai F., Hayakawa T., Furue MK., Mizuguchi H. Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1 α transduction. *J. Hepatol.*, 57, 628-636 (2012)
- 30) Takayama K., Kawabata K., Nagamoto Y., Kishimoto K., Tashiro K., Sakurai F., Tachibana M., Kanda K., Hayakawae T., Furue MK., Mizuguchi H. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. *Biomaterials*, 34, 1781-1789 (2013)
- 31) Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, Ikeda M, Kato N, Isomoto H, Tkashima F, Nakao K. Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells. *J Gastroenterol*, 47(2):195-202, 2012.
- 32) Tripathi LP, Kambara H, Moriishi K, Morita E, Abe T, Mori Y, Chen YA, Matsuura Y, Mizuguchi K: Proteomic Analysis of Hepatitis C Virus (HCV) Core Protein Transfection and Host Regulator PA28gamma Knockout

in HCV Pathogenesis: A Network-Based Study. *J. Proteome Res.*, 11: 3664-3679, 2012

33) Takeda M, Ikeda M, Ariumi Y, Wakita T, Kato N. Development of hepatitis C virus production reporter assay systems using two different hepatoma cell lines. *J. Gen. Virol.*, 93(7):1422-31,2012.

34) Takeda M, Ikeda M, Mori K, Yano M, Ariumi Y, Dansako H, Wakita T, Kato N. Raloxifene inhibits hepatitis C virus infection and replication. *FEBS Open Bio.*, 2:279-283,2012.

35) Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K. Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star *Alloeocomatella polycladia*. *Mar. Drugs*, 10:744-761,2012.

36) Yamashita A, Abdus K, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Thuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K: Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star *Alloeocomatella polycladia*. *Marine Drugs* 2012; 10(4):744-761.

2. 学会発表および講演など

平成22年度

1. T Wakita. HCV replication and persistent infection, Cold Spring Harbor Asia Conference on Emerging Infectious Diseases: Emerging Viruses and the Control of Viruses, Cold Spring Harbor Asia Conference, October 18 - 22, 2010, Suzhou Dushu Lake Conference Center, Suzhou, China

2. T Wakita. HCV replication in vitro, The 7th Single Topic Conference: Hepatitis C Virus, Asia Pacific Association of the Study of the Liver (APASL), Makuhari Messe, Chiba, Japan (2010 Dec 17-18)

3. R Suzuki, D Akazawa, K Ishii, Y Matsuura, T Wakita,

T Suzuki, Efficient production of *trans*-complemented hepatitis C virus particles: Use for study of viral entry process, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

4. T Masaki, S Matsunaga, H Takahashi, T Kato, Y Endo, T Sawasaki, T Wakita, T Suzuki, Identification of hepatitis C virus NS5A-associated protein kinases, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

5. N Watanabe, A Murayama, M Saeed, T Date, T Kato, T Wakita, Analysis of envelope N-glycans required for HCV lifecycle, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

6. H Yokokawa, D Akazawa, M Moriyama, N Nakamura, H Mochizuki, T Suzuki, T Kato, K Ishii, T Wakita, Development of a Purification Method of Highly Purified HCV Virion for Industrial Production, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

7. M Moriyama, H Yokokawa, D Akazawa, K Nishimura, N Nakamura, H Mochizuki, T Suzuki, T Kato, K Ishii, T Wakita, The exploration of effective adjuvant for HCV vaccine to induce neutralizing immunoglobulin in mice, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

8. K Watashi, K Shimotohno, K-T Jeang, T Wakita, Inhibition of HCV replication by a small molecule that suppresses microRNA pathway, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

9. M Saeed, T Kato, M Shiina, M Imamura, K Chayama, Y Choi, K Krawczynski, T. J Liang, T Wakita, Hepatitis C Virus JFH-1 Strain That Adapted In Vivo Acquired Abilities for Efficient Virus Production and Anti-apoptosis, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)

10. T Kanda, R Tamura, F Imazeki, S Nakamoto, S Wu, T Roger, T Wakita, H Shirasawa, O Yokosuka, HEPATITIS C VIRUS NS5A ATTENUATES LPS-INDUCED APOPTOSIS BY DOWNREGULATION OF TOLL-LIKE RECEPTOR 4 SIGNALING PATHWAY, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)
11. Y OKAMOTO, T MASAKI, A MURAYAMA, T KATO, H WATANABE, T Wakita, Affects of NS5a replacement in HCV JFH-1 genome on viral replication and infectious particle production in cell culture, 17th International Meeting on Hepatitis C and Related Viruses. Pacifico Yokohama, Yokohama, Japan (2010, Sep. 10-14)
12. Y Kushima, T Wakita, M Hijikata: The hepatitis C virus particle requires a disulfide-bonded dimer of the core protein. 17th International symposium on hepatitis C virus and related viruses. Yokohama, Japan, Sept 10-14 2010
13. Y Qi, HH. Aly, C Tsutsui, T Fujita, M Hijikata: IRF7 dependent IFN-alpha response in the early phase of the viral infected hepatocytes. 17th International symposium on hepatitis C virus and related viruses. Yokohama, Japan, Sept 10-14 2010
14. Y Kushima, T Wakita, M Hijikata: The hepatitis C virus particle requires a disulfide-bonded dimer of the core protein. The Association of Pacific Rim University, Research symposium on Interface between Molecular Biology and Nano Biology, Kyoto, Japan, Nov. 24-26 2010
15. Y Abe, T Wakita, M Hijikata: Chemical biological analysis for a mechanism of infectious HCV particle production. The Association of Pacific Rim University, Research symposium on Interface between Molecular Biology and Nano Biology, Kyoto, Japan, Nov. 24-26 2010
16. Kambara H., Taguwa S., Fujita N., Noda T., Yoshimori T., Moriishi K., Matsuura Y. Inhibition of autophagy induces lysosomal vacuolation in cells replicating HCV. 17th International Symposium on Hepatitis C virus and Related Viruses, September 10-14, 2010 Yokohama. Japan.
17. Taguwa S., Kambara H., Fujita N., Noda T., Yoshimori T., Moriishi K., Matsuura Y. HCV replication enhances secretion of an immature cathepsin B through induction of an incomplete autophagy. 17th International Symposium on Hepatitis C virus and Related Viruses, September 10-14, 2010 Yokohama. Japan.
18. Moriishi K., Shoji I., Mori Y., Suzuki R., Suzuki T., Kataoka C., Matsuura Y. Involvement of PA28gamma in the propagation of HCV. . 17th International Symposium on Hepatitis C virus and Related Viruses, September 10-14, 2010 Yokohama. Japan.
19. Masanori Ikeda, Kyoko Mori, Takahide Nakazawa, Yasuo Ariumi, Hiromichi Dansako, Nobuyuki Kato. Development of genome-length HCV RNA replication assay systems derived from different HCV strains using HuH-7 and Li23 cells. 17th international symposium on hepatitis C virus and related viruses, Yokohama, Japan, 2010.
20. Kyoko Mori , Masanori Ikeda, Yasuo Ariumi, Hiromichi Dansako, Takaji Wakita, Nobuyuki Kato. Anti-HCV mechanism of ribavirin in novel HCV replication cell systems. 17th international symposium on hepatitis C virus and related viruses, Yokohama, Japan, 2010.
21. Yasuo Ariumi, Masanori Ikeda, Takaji Wakita, Nobuyuki Kato. Role of distinct DDX DEAD-box RNA helicases in HCV RNA replication. 17th international symposium on hepatitis C virus and related viruses, Yokohama, Japan, 2010
22. Akito Nozaki, Kazushi Numata, Manabu Morimoto, Masaaki Kondo, Masanori Ikeda, Nobuyuki Kato, Katsuaki Tanaka. Hydroxyurea suppresses hepatitis C virus replication in human: a phase I trial of oral hydroxyurea in chronic hepatitis C patients. 17th international symposium on hepatitis C virus and related viruses, Yokohama, Japan, 2010.
23. Yoshiyasu Shinohara, Koji Fujita, Hironori Mawatari, Masato Yoneda, Yuichi Nozaki, Hiroyuki Kirikoshi,

- Kento Imajo, Kaori Suzuki, Kengo Funakoshi, Masanori Ikeda, Nobuyuki Kato, Shin Maeda, Atsushi Nakajima, Satoru Saito. Clearance of the hepatitis C virus replicon by interferon-alpha treatment restored the signal pathway involving JNK. 17th international symposium on hepatitis C virus and related viruses, Yokohama, Japan, 2010.
24. Yoshiyasu Shinohara, Koji Fujita, Yuichi Nozaki, Kento Imajo, Hironori Mawatari, Masato Yoneda, , Hiroyuki Kirikoshi, Kengo Funakoshi, Masanori Ikeda, Nobuyuki Kato, Shin Maeda, Atsushi Nakajima, Satoru Saito. Hepatitis C Virus infection changes the lipoprotein profiles in the replicon system. 17th international symposium on hepatitis C virus and related viruses, Yokohama, Japan, 2010.
25. Takebe, Y., Uenishi, R., Hase, S., Tsuchiura, T., Liao, H., McMahan, J.B., and O' Keefe, B, R. Effective protection of HCV infection by HCV entry inhibitor griffithsin, newly identified carbohydrate binding protein, in mouse infection model. 7th International symposium on Hepatitis C virus and related viruses. September 10-14, 2010, Yokohama, Japan.
26. Yoshida T, Satoh F, Kondoh M, Mizuguchi H, Yagi K. Development of an adenovirus vector-mediated assay system for Hepatitis C virus replication. 50th annual meeting of the American society for cell biology. December 11-15, 2010. Philadelphia, USA
27. 脇田隆字, 「C型肝炎ウイルスの複製増殖および持続感染機構」、第23回肝臓フォーラム（東部）、日本工業倶楽部会館（2010, 6.5）
28. 脇田隆字, 「C型肝炎ウイルスの複製増殖および持続感染機構の解析」、第9回KMU研究推進セミナー、北陸がんプロ教育セミナー、金沢医科大学病院 新館12階大会議室（2010, 6.18）
29. 脇田隆字, 「C型肝炎ウイルスの培養細胞でのウイルス複製と生体における持続感染機構」、京都大学ウイルス研究所 学術講演会、京都大学 京大会館 101号室（2010, 7.15）
30. 脇田隆字, 「C型肝炎ウイルスの複製増殖および持続感染機構の研究」、第17回ソニックフォーラム、ソニックシテイビル 6階602会議室（2010, 11.25）
31. 政木隆博、松永智子、高橋宏隆、加藤孝宣、宮村達男、遠藤弥重太、澤崎達也、脇田隆字、鈴木哲朗、HCVNS5A 蛋白のリン酸化に関する新規セリン/スレオニンキナーゼの探索、第46回日本肝臓学会総会、ホテルメトロポリタン山形、(2010, 5.27-28)、ワークショップ5「C型肝炎ウイルスの感染・増殖メカニズムと臨床応用」
32. 有海康雄、黒木美沙緒、土方誠、Qi Yue、池田正徳、脇田隆字、下遠野邦忠、加藤宜之、ESCRT小胞輸送系のHCV産生への関与、日本ウイルス学会第58回学術集会、あわぎんホール(2010, 11.7-9)、シンポジウム6 ウイルス培養系を用いたC型肝炎ウイルスの性状と病原性の解明
33. 加藤孝宣、岡本有加、村山麻子、政木隆博、脇田隆字、HCVの増殖適応変異とその意義、日本ウイルス学会第58回学術集会、あわぎんホール(2010, 11.7-9)、シンポジウム6 ウイルス培養系を用いたC型肝炎ウイルスの性状と病原性の解明
34. 相崎英樹、後藤耕司、松本喜弘、山本真民、佐藤慈子、高橋信弘、本島清人、深澤征義、花田賢太郎、松浦善治、宮村達男、脇田隆字、鈴木哲朗、HCV粒子形成に関する脂肪滴周辺膜蛋白の機能解析、第46回日本肝臓学会総会、ホテルメトロポリタン山形、(2010, 5.27-28)
35. 鈴木亮介、齋藤憲司、赤澤大輔、石井孝司、松浦善治、脇田隆字、鈴木哲朗、C型肝炎ウイルスの *trans-packaging* 型粒子を用いた感染機構の解析、日本ウイルス学会第58回学術集会、あわぎんホール(2010, 11.7-9)
36. 白砂圭崇、齊藤恭子、村上裕子、深澤秀輔、鈴木哲朗、脇田隆字、花田賢太郎、千葉丈、深澤征義、感染・増殖能が上昇したC型肝炎ウイルス変異株の分離と性状解析、日本ウイルス学会第58回学術集会、あわぎんホール(2010, 11.7-9)
37. 阿部雄一、Aly Hassan Hussein、脇田隆字、下遠野邦忠、土方誠、感染性HCV粒子産生に関わる新規細胞内シグナル経路の探索、日本ウイルス学会第58回学術集会、あわぎんホール(2010, 11.7-9)
38. 土方誠、阿部雄一、Aly Hassan Hussein、齊月、

脇田隆字、下遠野邦忠、臨床分離 HCV 株の培養と性状、日本ウイルス学会第 58 回学術集会、あわぎんホール(2010, 11.7-9)

39. 深澤秀輔、鈴木哲朗、脇田隆字、村上裕子、C 型肝炎ウイルス (HCV) に阻害作用を示す物質の探索、日本ウイルス学会第 58 回学術集会、あわぎんホール(2010, 11.7-9)

40. 渡士幸一、下遠野邦忠、Kuan-Teh Jeang、脇田隆字、マイクロ RNA 経路の C 型肝炎ウイルス複製における意義とその創薬標的としての役割、日本ウイルス学会第 58 回学術集会、あわぎんホール(2010, 11.7-9)

41. 江角真理子、石橋真理子、鶴田浩一、山口裕美、菊田幸子、榊原由子、脇田隆字、C 型肝炎ウイルス感染に対する自然防御について、日本ウイルス学会第 58 回学術集会、あわぎんホール(2010, 11.7-9)

42. 渡邊則幸、村山麻子、Mohsan Saeed、伊達朋子、加藤孝宣、相崎英樹、脇田隆字、HCV エンベロープタンパク質に付加される N 型糖鎖の機能解析、日本ウイルス学会第 58 回学術集会、あわぎんホール(2010, 11.7-9)

43. 久島透嘉、脇田隆字、土方誠 : Core による S-S 結合型二量体は C 型肝炎ウイルスの粒子形成に必須である、第 58 回日本ウイルス学会学術総会、平成 22 年 11 月 7-9 日、徳島 2010

44. 坂本知行、田中靖人、杉山真也、山川慶洋、松浦健太郎、日下部篤宣、新海登、木村吉秀、勝美康平、城卓志、溝上雅史、B 型肝炎ウイルス Genotype G の共感染下における複製メカニズムの検討。第 46 回日本肝臓学会総会、2010 年 5 月、山形。

45. 森石恆司、松浦善治、HCV による脂質代謝障害の分子機序、第 58 回日本ウイルス学会学術集会、2010 年 11 月 7-9 日、徳島

46. 寒原裕登、田鍬修平、藤田尚信、野田健司、森石恆司、吉森 保、松浦善治、C 型肝炎ウイルスはオートファジーを誘導して持続感染を成立させる、第 58 回日本ウイルス学会学術集会、2010 年 11 月 7-9 日、徳島

47. 加藤大志、森嘉生、寒原裕登、要祐喜、谷英樹、阿部隆之、神谷亘、森石恆司、松浦善治、核小体蛋

白質 B23 は C 型肝炎ウイルス複製を抑制する第 58 回日本ウイルス学会学術集会、2010 年 11 月 7-9 日、徳島

48. 池田 正徳、森 京子、武田 緑、中澤 貴秀、有海 康雄、團迫 浩方、加藤 宣之 異なる HCV 株、細胞株を用いた HCV RNA 複製培養細胞での薬剤評価 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

49. 森 京子、池田 正徳、有海 康雄、團迫 浩方、脇田 隆字、加藤 宣之 リバビリンの抗 HCV 活性を決定する因子の解析 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

50. 上田 優輝、森 京子、池田 正徳、有海 康雄、加藤 宣之 異なる細胞株を用いて開発した HCV-RNA 複製系による抗 HCV 活性が報告されている薬剤等の再評価 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

黒木 美沙緒、有海 康雄、池田 正徳、團迫 浩方、脇田 隆字、加藤 宣之 がん抑制因子 PML は HCV ライフサイクルに必須である 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

51. 田中寅彦、黒田和道、榎島誠、池田正徳、加藤宣之 C 型肝炎ウイルス NS4B と lipid droplet の相互作用 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

52. 篠原義康、藤田浩司、米田正人、野崎雄一、今城健人、鈴木香峰理、馬渡弘典、桐越博之、船越健悟、池田正徳、加藤宣之、前田慎、中島淳、斉藤聡 HCV 感染におけるリポ蛋白代謝の解析 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

53. 藤本雄介、前田信哉、榎本信幸、池田正徳、加藤宣之、伊藤正彦、山下篤哉 抗 HCV NS2 タンパク活性阻害剤 High throughput screening のための HCV subgenomic replicon 細胞の構築 第 58 回日本ウイルス学会学術集会、徳島、2010 年 10 月

54. 山下篤哉、古田篤史、松田泰嘉、谷英典、藤田統、秋光信佳、田中淳一、池田正徳、加藤宣之、前川信哉。榎本信幸、伊藤正彦、常田聡、関口勇地、野田尚宏 沖縄産 ウミシダ (Alloeocomatella polycladia)抽出物の抗 HCV NS3 helicase 阻害活性に

よる HCV 増殖抑制効果 第 58 回日本ウイルス学会
学術集会、徳島、2010 年 10 月

55. 池田正徳、森京子、武田緑、中澤貴秀、有海康
雄、団迫浩方、加藤宣之 IL28B 領域の SNP が異な
る肝細胞株 (HuH-7、Li23)における抗 HCV 剤の感受
性 第 33 回日本分子生物学会年会、神戸、2010 年
12 月

56. 田中寅彦、黒田和道、槇島誠、池田正徳、加藤
宣之 C 型肝炎ウイルス非構造タンパク質 4B にお
ける lipid droplet との相互作用部位の同定 第 33
回日本分子生物学会年会、神戸、2010 年 12 月

57. 飯倉南、降幡知己、池田正徳、加藤宣之、千葉
寛 C 型肝炎治療薬リバビリンの薬効発現における
細胞内リバビリン取込み機構の重要性 第 33 回日
本分子生物学会年会、神戸、2010 年 12 月

58. 篠原義康、藤田浩司、米田正人、野崎雄一、今
城健人、鈴木香峰理、馬渡弘典、桐越博之、船越健
悟、池田正徳、加藤宣之、前田慎、中島淳、斉藤聡
HCV 感染における ER ストレスを介した細胞死の検
討 第 33 回日本分子生物学会年会、神戸、2010 年
12 月

59. 加藤孝宣、脇田隆宇. C 型肝炎ウイルスの生体内
での感染様式と培養細胞での増殖能、第 46 回日本
肝臓学会総会、ホテルメトロポリタン山形、(2010,
5.27-28)

60. 川端健二、水口裕之. 遺伝子導入を用いた iPS 細
胞の肝細胞への高効率分化誘導法、第 10 回日本再生
医療学会総会、2011 年 3 月、東京.

61. 高山和雄、稲村充、川端健二、田代克久、形山
和史、櫻井文教、古江一楠田美保、水口裕之. SOX17
遺伝子導入によるヒト ES・iPS 細胞からの内胚葉お
よび胚体外内胚葉への選択的分化誘導、第 10 回日本
再生医療学会総会、2011 年 3 月、東京.

62. 田代克久、川端健二、櫻井文教、水口裕之. 幹
細胞の分化誘導系におけるアデノウイルスベクター
の有用性、第 60 回日本薬学会近畿支部総会・大会、
2010 年 10 月、大阪.

63. 高山和雄、稲村充、田代克久、形山和史、櫻井
文教、古江一楠田美保、川端健二、水口裕之. SOX17
遺伝子導入によるヒト ES・iPS 細胞からの内胚葉お

よび胚体外内胚葉への選択的分化誘導、第 9 回次
世代を担うファーマ・バイオフィォーラム 2010、2010
年 10 月、京都.

64. 稲村充、川端健二、高山和雄、田代克久、形山
和史、櫻井文教、古江一楠田美保、水口裕之. HEX
遺伝子の導入によるヒト ES 細胞やヒト iPS 細胞から
の効率良い肝幹細胞への分化誘導、第 16 回肝細胞研
究会、2010 年 6 月、秋田.

65. 高山和雄、稲村充、田代克久、形山和史、櫻井
文教、古江一楠田美保、川端健二、水口裕之. SOX17
遺伝子導入によるヒト ES・iPS 細胞からの内胚葉お
よび胚体外内胚葉への選択的分化誘導、第 16 回肝細
胞研究会、2010 年 6 月、秋田.

66. 吉田孟史、近藤昌夫、水口裕之、八木清仁. RNA
polymerase I 発現系を利用した HCV 複製評価系の
開発. 第 17 回肝細胞研究会、平成 22 年 6 月、秋
田

67. 山岸喜彰、吉田猛史、近藤昌夫、八木清仁. 感
染受容体発現バキュロウイルスを用いた HCV 感染
機構の解解析. 日本薬学会第 131 年会、平成 23 年 3
月、静岡

平成 23 年度

1. T Wakita. Hepatitis C Virus Infection and Replication,
annual meeting of Prof. Juei-Low Sung' s Research
Foundation, Taipei, Taiwan (2011, 8. 6)

2. T Wakita. HCV RNA replication and drug
development. The 8th APASL Single Topic Conference
Beijing, China (2011, 10. 7)

3. T Wakita. Hepatitis C virus replication in vitro and
persistent infection in vivo: mechanistic analysis and
antiviral development, Singapore-Japan Forum on
Emerging Concepts in Microbiology, National University
of Singapore, Singapore (2011 Nov 15-16)

4. T Wakita. Hepatitis C virus replication in vitro and
persistent infection in vivo: mechanistic analysis and
antiviral development, Challenges to overcome Emerging
Infectious Diseases in South-eastern Asia, Siran Kaikan,
Kyoto University. Kyoto (2012 Jan 13)

5. T Wakita. Hepatitis C virus replication models and anti-viral development, The 1st International Symposium on Latent TGF-beta Activation Reaction, RIKEN Kobe Inst, Ctr. For Delop Biol, Auditorium, Kobe (2012 Feb 25)
6. Takebe, Y., Uenishi, R., Tani. H., Suzuki, R., Hase, S., Akazawa, D., Takagi, M., Tsuchiura, T., Nagasawa, K., Suzuki, T., Irie, K., Shinya, K., Wakita, T., Matsuura, Y., Patel, A., Small molecules that elicit anti-HCV activity through down-modulation of HCV entry receptors, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
7. N Watanabe, K Futai, H Suga, T Wakita, E2 binding peptide identified by RAPID system inhibited HCV infection, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
8. K Goto, T Kimura, K Watashi, R Suzuki, S Yamagoe, T Miyamura, K Moriya, H Yotsuyanagi, K Koike, T Suzuki, T Wakita, H Aizaki, Identification of novel NS5A-associated proteins in the host-cell membrane fraction and their role in HCV life cycle, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
9. R Suzuki, T Suzuki, K Saito, M Matsuda, K Watashi, Y Matsuura, T Wakita, H Aizaki, IDENTIFICATION AND CHARACTERIZATION OF SIGNAL PEPTIDASE COMPLEX 1 THAT INTERACTS WITH HEPATITIS C VIRUS NS2 PROTEIN AND IS INVOLVED IN THE VIRAL ASSEMBLY, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
10. J Law, D Hockman, S Frey, R Khoshy, T Wakita, J Bukh, C Rice, M Houghton, Does a vaccine derived from a single HCV strain elicit broadly cross-neutralising antibodies in humans?, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
11. Y Okamoto, T Masaki, A Murayama, T Wakita, T Kato, Development of chimeric hepatitis C virus expressing NS5A from strains of genotypes 1 and 2: virus production and susceptibility to NS5A inhibitor, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
12. M Fukasawa, Y Shirasago, K Saito, Y Murakami, H Fukazawa, T Suzuki, R Suzuki, T Wakita, K Hanada, J Chiba, Isolation of a highly infectious hepatitis C virus with adaptive mutations, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
13. H Yokokawa, D Akazawa, M Moriyama, N Nakamura, T Kato, K Ishii, T Wakita, Development of purification method for HCV particles using chromatographic technique, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
14. M Esumi, S Kikuta, H Yamaguchi, S Nakajima, M Ishibashi, T Wakita, Serum and trypsin inhibitors inhibit the early step of hepatitis C virus infection, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
15. M Moriyama, D Akazawa, H Yokokawa, K Nishimura, N Nakamura, H Mochizuki, T Kato, K Ishii, T Wakita, Immunological memory response to induce neutralizing immunoglobulin in HCV particles-immunized mice, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
16. K Watashi, N Uchida, R Suzuki, H Aizaki, T Wakita, Identification of small molecules affecting late steps of hepatitis C virus life cycle, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
17. N Uchida, K Watashi, R Suzuki, H Aizaki, J Chiba, T Wakita, Halopemide inhibited a post-assembly step in hepatitis C virus life cycle, 18th International Meeting on Hepatitis C and Related Viruses. Seattle Sheraton Hotel, Seattle, USA (2011, Sep. 8-12)
18. N Watanabe, A Murayama, M Saeed, T Date, T Kato,

- H Aizaki, T Wakita, Identification and analysis of envelope N-glycans required for HCV lifecycle, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
19. Y Okamoto, T Masaki, A Murayama, A Nomoto, T Wakita, T Kato, Strain Specific Susceptibility to The Hepatitis C Virus NS5A Inhibitor, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
20. R Suzuki, K Saito, M Matsuda, K Watashi, Y Matsuura, T Wakita, T Suzuki, H Aizaki, Identification of a host factor that interacts with hepatitis C virus NS2 protein and is involved in the viral assembly, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
21. A Murayama, N Sugiyama, S Yoshimura, M Ishihara-Sugano, T Wakita, T Kato, Efficient HCV production system using HuH-7 subclone with high virus assembly efficiency, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
22. H Aizaki, Y Matsumoto, K Goto, K Watashi, R Suzuki, M Fukasawa, K Hanada, S Sato, N Takahashi, Y Matsuura, K Motojima, T Miyamura, T Suzuki, T Wakita, Identification of lipid droplet-associated membrane proteins that are involved in HCV production, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
23. Y Matsumoto, K Watashi, R Suzuki, T Matsuura, T Suzuki, T Miyamura, K Wake, T Wakita, H Aizaki, Antiviral activity of glycyrrhizic acid against hepatitis C virus in vitro, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
24. K Watashi, N Uchida, R Suzuki, H Aizaki, T Wakita, Identification of small molecules affecting late steps of hepatitis C virus life cycle, XV International Congress of Virology. Sapporo Convention Center, Sapporo, Japan (2011, Sep. 11-16)
25. K Watashi, N Uchida, R Suzuki, H Aizaki, T Wakita, Screening of small molecules affecting the production of hepatitis B virus, 2011 International Meeting on Molecular Biology of Hepatitis B Viruses, Oct 9-12, Holliday Inn Walt Disney World Resort, FL USA
26. Murayama A, Sugiyama N, Yoshimura S, Ishihara-Sugano M, Wakita T, Kato T. Efficient HCV production system using HuH-7 subclone with high virus assembly efficiency. 18th International Symposium on Hepatitis C Virus and Related Viruses. September 8-12, 2011. Seattle, USA
27. Matsumura T, Kato T, Tasaka-Fujita M, Murayama A, Masaki T, Wakita T, Imawari M. 25-hydroxy- vitamin D inhibits hepatitis C virus replication and production of the infectious viruses. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. November 4-8, 2011. San Francisco, USA
28. Y.Kushima, Y Abe, T Wakita, K Shimotohno, M Hijikata: Novel targets for anti HCV drugs preventing infectious virus particle production. The 3rd JCA-AACR Special Joint Conference, The Latest Advances in Liver Cancer Research: From Basic Science to Therapeutics, Chiba, Japan, March 1-3, 2011.
29. Y Abe, H H. Aly, T Wakita, K Shimotohno, M Hijikata: Identification of signal pathway involved in infectious Hepatitis C virus (HCV) particle production. The 6th International symposium of institute network. Tokyo, Japan, June 9-10, 2011
30. Y Abe, T Wakita, K Shimotohno, M Hijikata: Identification of signal pathway involved in infectious Hepatitis C virus particle production. 18th International symposium on hepatitis C virus and related viruses. Seattle, USA, Sept 8-12, 2011
31. Y Abe, H Aly, T Wakita, M Hijikata: Identification of signal pathway involved in infectious Hepatitis C virus (HCV) particle production. 第34回日本分子生物学会総会 2011年12月13日～16日、横浜
32. Yamashita A., Fujimoto Y., and Moriishi K. Marine natural products as a source of the novel antiviral agent targeting to HCV NS3 helicase XV International Congress of Virology., September 11-16, 2011 Sapporo.

Japan

33. Fujimoto Y., Yamashita A., and Moriishi K. Inhibitory effect of marine natural products on the replication of hepatitis C virus., September 11-16, 2011 Sapporo. Japan
34. Kambara H., Tani H., Mori Y., Abe T., Katoh H., Fukuhara T., Taguwa S., Moriishi K., and Matsuura Y. Involvement of cyclophilin B in the replication of Japanese encephalitis virus. September 11-16, 2011 Sapporo. Japan
35. Kawakami, K., Kasai, H., Yamashita, A., Enomoto, N., Matsuura, Y., Kusunoki, M., and, Moriishi K. Regulation of HCV replication by FKBP8-dependent or - independent Hsp90 activity.. 18th International Symposium on Hepatitis C virus and Related Viruses, September 8-12, 2011 Seattle. USA.
36. Kawakami, K., Kasai, H., Yamashita, A., Enomoto, N., Matsuura, Y., Kusunoki, M., and, Moriishi K. Regulation of HCV replication by FKBP8-dependent or -independent Hsp90 activity.. 第34回日本分子生物学会総会 2011年12月13日～16日、横浜
37. Kataoka C., Tani H., Kaname Y., Taguwa S., Abe T., Fukuhara T., Moriishi K., and Matsuura Y. Baculovirus GP64-mediated entry into mammalian cells. 第34回日本分子生物学会総会 2011年12月13日～16日、横浜
38. Mori K, Hiraoka O, Ikeda M, Ariumi Y, Hiramoto A, Wataya Y, Kato N. A host factor determining the anti-HCV activity of ribavirin. 70th Annual Meeting of the Japanese Cancer Association, 2011. Oct, Nagoya
39. Sejima H, Mori K, Ariumi Y, Ikeda M, Kato N. Identification of host genes showing differential expression profiles in cell-based long-term HCV RNA replication. 70th Annual Meeting of the Japanese Cancer Association, 2011. Oct. Nagoya
40. Ikeda M, Takeda M, Ariumi Y, Wakita T, Kato N. The role of geranylgeranyl transferase II in hepatitis C virus life cycle. The 34th Annual Meeting of the Molecular Biology Society in Japan, 2011. Dec., Yokohama
41. Ikeda M, Takeda M, Ariumi Y, Waikita T, Kato N. Geranylgeranyl transferase II is essential for HCV RNA replication. 18th international symposium on

hepatitis C virus and related viruses, 2011 Sep., Seattle, US

42. Takeda M, Ikeda M, Ariumi Y, Waikita T, Kato N. Development of HCV JFH-1 reporter assay systems using different human hepatoma cell lines. Meetings of the Three Divisions of the International Union of Microbiological Societies 2011, 2011 Sep., Sapporo, Japan
43. Mori K, Hiraoka O, Ikeda M, Hiramoto A, Wataya Y, Kato N. Identification of a host factor determining the anti-HCV activity of ribavirin. 18th international symposium on hepatitis C virus and related viruses, 2011 Sep., Seattle, USA
44. Ueda Y, Mori K, Ariumi Y, Ikeda M, Kato N. Plural assay systems derived from different cell lines and HCV strains are required for the objective evaluation of anti-HCV reagents. 18th international symposium on hepatitis C virus and related viruses, 2011 Sep., Seattle, USA
45. Sejima S, Mori K, Ariumi Y, Ikeda M, Kato N. Identification of host genes showing differential expression profiles in cell-based long-term replication of hepatitis C virus RNA. Meetings of the Three Divisions of the International Union of Microbiological Societies 2011, 2011 Sep., Sapporo, Japan
46. Kuroki M, Ariumi Y, Ikeda M, Dansako H, Wakita T, Kato N. HCV production requires the PML tumor suppressor protein. 18th international symposium on hepatitis C virus and related viruses, 2011 Sep., Seattle, USA
47. Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijilata M, Maki M, Ikeda M, Wakita T, Kato N. Hepatitis C virus hijacks P-Body and stress granule components around lipid droplets. 18th international symposium on hepatitis C virus and related viruses, 2011 Sep., Seattle, USA
48. Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Mizokami M, Watanabe M. ITPA gene variant protects against treatment-induced anemia and improves viral clearance by

- pegylated interferon-alfa and ribavirin therapy in chronic hepatitis C patients. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #1016)
49. Kakinuma S, Kamiya A, Sakamoto N, Nakauchi H, Watanabe M. MMP-2 and MMP-14 derived from donor cells enhance therapeutic efficacy of liver cell transplantation in mice. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #670)
50. Kusano-Kitazume A, Sakamoto N, Okuno Y, Yamamoto M, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyohashi K, Nitta S, Murakawa M, Hagiwara M, Watanabe M. A high-content screening assay using infectious fluorescence-tagged hepatitis C virus reveals candidates for small molecule inhibitors of viral entry. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #383)
51. Kiyohashi K, Kakinuma S, Kamiya A, Sakamoto N, Nakauchi H, Watanabe M. Loww of Wnt5A promotes biliary differentiation of murine hepatic stem/progenitor cells. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Oral presentation #176)
52. Itsui Y, Sakamoto N, Yauchi T, Watanabe M. Antiviral effect of a novel interferon-inducible protein, IFI-27, against hepatitis C virus replication. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #2086)
53. Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Watanabe M. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #2040)
54. Kurosaki M, Itakura J, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Asahina Y, Tanaka Y, Mizokami M, Sakamoto N, Enomoto N, Izumi N. Prediction model of ribavirin-induced anemia incorporating ITPA genotype could identify chronic hepatitis C patients at high risk of relapse among virological responders to pegylated-interferon and ribavirin. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #982)
55. Matsuura K, Tanaka Y, Nishida N, Sugiyama M, Watanabe T, Sugauchi F, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsushashi H, Nishiguchi S, Hino K, Kaneko S, Nojiri S, Joh T, Tokunaga K, Mizokami M. IL28B and ITPA gene variants correlate with treatment efficacy in pegylated-interferon plus ribavirin therapy for chronic hepatitis C. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #994)
56. Kurosaki M, Sakamoto N, Matsuura K, Kakinuma S, Nakagawa M, Asahina Y, Enomoto N, Izumi N. Mutations in the interferon sensitivity determining region of HCV, age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy. 62th. Annual Meeting of American Association for the Study of Liver Diseases. Nov-4-2011. San Francisco, CA. (Poster #995)
57. T Yoshida, F Satoh, W Akihiro, M Kondoh, H Mizuguchi, N Sakamoto, K Yagi. Development of an RNA polymerase I-driven adenoviral vector and its application in an HCV replication assay. 18th. International Meeting on Hepatitis C Virus & Related Viruses. Sep-8-2011. Seattle, WA
58. N Sakamoto, Y Funaoka, G Suda, M Nakagawa, S Kakinuma, M Watanabe. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. 18th. International Meeting on Hepatitis C Virus & Related Viruses. Sep-8-2011. Seattle, WA
59. S Nitta, N Sakamoto, M Tasaka-Fujita, K Kiyohashi, A Kusano-Kitazume, M Murakawa, K Yoshino, K

- Mishima, S Kakinuma, M Nakagawa, M Watanabe. HCV-NS4B targets STING and abrogates RIG-I-mediated type-I interferon- dependent innate immune response. 18th. International Meeting on Hepatitis C Virus & Related Viruses. Sep-8-2011. Seattle, WA
60. Y Yamagishi, T Yoshida, M Kondoh, H Mizuguchi, N Sakamoto, A Watari, K Yagi. Development of RNA pol-driven adenovirus vector expressing hepatitis C virus replicon. Experimental Biology 2011. Apr-13-2011. Washington, DC
61. Takebe, Y., Uenishi, R., Tani. H., Suzuki, R., Akazawa, D., Takagi, M., Tsuchiura, T., Hase, S., Suzuki, T., Shinya, K., Wakita, T., Matsuura, Y., Patel, A. Small molecules that elicit strong anti-HCV activity through down-modulation of HCV entry receptors. 17th International symposium on Hepatitis C virus and related viruses. September 10-14, 2011, Seattle
62. M Hagiwara, Moduration of Pre-mRNA Splicing Patterns with Synthetic Chemicals and Their Clinical Applications, The UEHARA Memorial Foundation Symposium, Chembiomolecular Science: at Frontier of Chemistry and Biology, June 6-8, Tokyo, Japan
63. M Hagiwara, Visualization of Alternative Splithin with Multi-color Splicing Reporters and Their Application for Screen of Trans-acting Factors and Small Chemicals, The 16th Annual Meeting of the RNA Society/The RNA Society of Japan 13th Annual Meeting Kyoto, Japan June 14-18, 2011
64. M Hagiwara, Moduration of Pre-mRNA Splicing Patterns with Synthetic Chemicals and Their Clinical Applications, The UEHARA Memorial Foundation Symposium, Chembiomolecular Science: at Frontier of Chemistry and Biology, June 6-8, Tokyo, Japan
65. M Hagiwara, Visualization of alternative splicing and the therapeutic manipulation with chemical compounds, US-Japan Conference at City of Hope, August 4-5, USA
66. M Hagiwara New therapeutics by alteration of mRNA expression and processing with small chemicals", *International Chemical Biology Conference, October 11-12, USA, 2011*
67. M Hagiwara, New RNA-targetting therapeutics with protein kinase inhibitors, Protein kinases regulating RNA splicing, November 12-16, 2011, France
68. Sugauchi F, Tanaka Y, Matsuura K, Watanabe T, Tajiri K, Kishi H, Mizokami M. CROSS-GENOTYPE PROTECTION OF HBV AND A ROLE OF HBS ANTIGEN MUTATION IN IMMUNITY ESCAPE IN VITRO AND IN VIVO MODEL USING UPA/SCID MICE WITH HUMAN HEPATOCYTES. THE 62ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. NOVEMBER 4-8, 2011. San Francisco, USA
69. Sugiyama M, Tanaka Y, Nakanishi M, Sudoh M, Mizokami M. HOST SPHINGOLIPID BIOSYNTHESIS AS A THERAPEUTIC TARGET FOR HEPATITIS B VIRUS REPLICATION. THE 62ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. NOVEMBER 4-8, 2011. San Francisco, USA
70. Fujiwara K, Tanaka Y, Orito E, Acharya Subrat K, Joh T, Allison Robert D, Mizokami M. ANALYSIS OF A NOVEL "REPLACEMENT MUTATION " IN CORE PROMOTER OF HEPATITIS B VIRUS. THE 62ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. NOVEMBER 4-8, 2011. San Francisco, USA
71. Kimura W, Machii M, Sultana N, Hikosaka K, Sharkar MTK, Uezato T, Koseki H, Miura N. Reduced tendon differentiation in the Irx11 knockout mice. 70th Annual Meeting, of Society of Developmental Biology, July 21-25 2011, Chicago IL
72. K Takayama, M Inamura, K Kawabata, K Katayama, K Tashiro, F Sakurai, M Kusuda-Furue, H Mizuguchi: Efficient generation of mature hepatocytes from human pluripotent stem cells by HNF4 α transduction., 第26回日本薬物動態学会年会、広島、2011年11月16-18日
73. K Takayama, M Inamura, K Kawabata, K Katayama,